Mylan Inc.today announced that its subsidiary Mylan Pharmaceuticals Inc. received finalapproval from the U.S. Food and Drug Administration (FDA) for its AbbreviatedNew Drug Application (ANDA) for Levetiracetam Tablets, 1000 mg. LevetiracetamTablets are the generic version of UCB Pharma’s antiepileptic Keppra@. Thisadditional strength of Levetiracetam Tablets complements Mylan’s alreadyapproved and marketed strengths of 250 mg, 500 mg and 750 mg.Levetiracetam Tablets, 1000 mg had U.S. sales of approximately $136million for the 12 months ending Sept. 30 and is shipping immediately.
Related Articles Read More >
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
Eicos Sciences’ FDA-approved Aurlumyn promises to drastically reduce frostbite amputations
